• Molecular NameRidogrel
  • SynonymRidogrelum [INN-Latin]
  • Weight366.339
  • Drugbank_IDDB01207
  • ACS_NO110140-89-1
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.49
  • pkaN/A
  • LogD (pH=7, predicted)1.36
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.44
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds9
  • TPSA71.78
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyRidogrel is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin.
  • Absorption_valueN/A
  • Absorption (description)Rapidly absorbed after oral administration (30-60 min)
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding60.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A